Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Incyte's JAK inhibitor effective in PhII arthritis; dosing uncertainties remain

This article was originally published in Scrip

Executive Summary

Incyte has presented Phase II data for its JAK1 inhibitor INCB39110 in rheumatoid arthritis, adding to a growing body of evidence that the JAK class, used primarily in oncology also has potential in inflammation. However, the Incyte Phase II trial studied a relatively low two- or three-fold (depending on what is compared) dose range and it is not clear from the results presented so far that dosing has been precisely determined.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts